Skip to main content

Table 2 Drug-related adverse events of all grades that occurred in ≥ 5% of patients*

From: Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients

Event No. of Patients (%)
  APV 600 mg/RTV 100 mg BID (N = 158) APV 1200 mg BID (N = 53)
Gastrointestinal   
   Nausea 31 (20) 10 (19)
   Diarrhea 27 (17) 10 (19)
   Vomiting 10 (6) 5 (9)
Non-site specific   
   Fatigue 11 (7) 4 (8)
Neurology   
   Headache 9 (6) 2 (4)
   Paresthesia, oral/perioral 3 (2) 4 (8)
Endocrine and metabolic   
   Hypertriglyceridemia 11 (7) 0
Skin   
   Rashes 8 (5) 3 (6)
  1. *Adverse events were classified as drug-related based on the investigators' assessment of causality.